JP2008511610A - グリセロール分岐のポリエチレングリコール−ヒト成長ホルモン結合体、それらの製造方法及び使用方法 - Google Patents

グリセロール分岐のポリエチレングリコール−ヒト成長ホルモン結合体、それらの製造方法及び使用方法 Download PDF

Info

Publication number: JP2008511610A
Authority: JP; Japan
Prior art keywords: hgh; peg; growth hormone; conjugate; glycerol
Prior art date: 2004-08-31
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

JP2007529040A

Other languages

English (en)

Japanese (ja)

Inventor

エフ．フィン，ロリー

アール．シーゲル，ネッド

Original Assignee

ファルマシア・アンド・アップジョン・カンパニー・エルエルシー

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-08-31

Filing date

2005-08-25

Publication date

2008-04-17

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35708806&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2008511610(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2005-08-25 Application filed by ファルマシア・アンド・アップジョン・カンパニー・エルエルシー filed Critical ファルマシア・アンド・アップジョン・カンパニー・エルエルシー

2008-04-17 Publication of JP2008511610A publication Critical patent/JP2008511610A/ja

Status Pending legal-status Critical Current

Links

239000000854 Human Growth Hormone Substances 0.000 title claims abstract description 200
238000000034 method Methods 0.000 title claims abstract description 30
-1 polyethylene Polymers 0.000 title claims description 15
239000004698 Polyethylene Substances 0.000 title claims description 3
229920000573 polyethylene Polymers 0.000 title claims description 3
238000004519 manufacturing process Methods 0.000 title description 7
108010000521 Human Growth Hormone Proteins 0.000 claims abstract description 210
102000002265 Human Growth Hormone Human genes 0.000 claims abstract description 210
230000012010 growth Effects 0.000 claims abstract description 26
238000011282 treatment Methods 0.000 claims abstract description 21
208000037824 growth disorder Diseases 0.000 claims abstract description 8
208000012239 Developmental disease Diseases 0.000 claims abstract description 5
208000020832 chronic kidney disease Diseases 0.000 claims description 10
206010056438 Growth hormone deficiency Diseases 0.000 claims description 9
206010013883 Dwarfism Diseases 0.000 claims description 7
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 7
COLNVLDHVKWLRT-QMMMGPOBSA-N phenylalanine group Chemical group N[C@@H](CC1=CC=CC=C1)C(=O)O COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 7
208000022831 chronic renal failure syndrome Diseases 0.000 claims description 6
208000026928 Turner syndrome Diseases 0.000 claims description 4
201000000523 end stage renal failure Diseases 0.000 claims description 4
239000003862 glucocorticoid Substances 0.000 claims description 4
208000001145 Metabolic Syndrome Diseases 0.000 claims description 3
206010029748 Noonan syndrome Diseases 0.000 claims description 3
208000030886 Traumatic Brain injury Diseases 0.000 claims description 3
201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 3
125000003275 alpha amino acid group Chemical group 0.000 claims description 3
230000009529 traumatic brain injury Effects 0.000 claims description 3
208000011231 Crohn disease Diseases 0.000 claims description 2
208000013558 Developmental Bone disease Diseases 0.000 claims description 2
201000010374 Down Syndrome Diseases 0.000 claims description 2
208000010228 Erectile Dysfunction Diseases 0.000 claims description 2
208000001640 Fibromyalgia Diseases 0.000 claims description 2
206010049287 Lipodystrophy acquired Diseases 0.000 claims description 2
208000021642 Muscular disease Diseases 0.000 claims description 2
201000009623 Myopathy Diseases 0.000 claims description 2
208000001132 Osteoporosis Diseases 0.000 claims description 2
206010072610 Skeletal dysplasia Diseases 0.000 claims description 2
208000032851 Subarachnoid Hemorrhage Diseases 0.000 claims description 2
208000028208 end stage renal disease Diseases 0.000 claims description 2
201000001881 impotence Diseases 0.000 claims description 2
208000006132 lipodystrophy Diseases 0.000 claims description 2
210000003643 myeloid progenitor cell Anatomy 0.000 claims description 2
208000026139 Memory disease Diseases 0.000 claims 1
238000010276 construction Methods 0.000 claims 1
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 abstract description 99
230000006320 pegylation Effects 0.000 abstract description 13
239000008194 pharmaceutical composition Substances 0.000 abstract description 4
229920001223 polyethylene glycol Polymers 0.000 description 107
150000001299 aldehydes Chemical class 0.000 description 42
229920000642 polymer Polymers 0.000 description 34
108090000623 proteins and genes Proteins 0.000 description 30
239000000122 growth hormone Substances 0.000 description 28
235000018102 proteins Nutrition 0.000 description 27
102000004169 proteins and genes Human genes 0.000 description 27
102000018997 Growth Hormone Human genes 0.000 description 26
108010051696 Growth Hormone Proteins 0.000 description 26
230000001965 increasing effect Effects 0.000 description 24
241000894007 species Species 0.000 description 23
239000000126 substance Substances 0.000 description 21
241001465754 Metazoa Species 0.000 description 18
241000700159 Rattus Species 0.000 description 18
239000003814 drug Substances 0.000 description 18
238000006243 chemical reaction Methods 0.000 description 15
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 15
238000009739 binding Methods 0.000 description 14
101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 13
102100037852 Insulin-like growth factor I Human genes 0.000 description 13
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
108020003175 receptors Proteins 0.000 description 12
102000005962 receptors Human genes 0.000 description 12
238000012360 testing method Methods 0.000 description 12
239000000556 agonist Substances 0.000 description 11
235000019786 weight gain Nutrition 0.000 description 11
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
239000000872 buffer Substances 0.000 description 10
239000011541 reaction mixture Substances 0.000 description 10
230000004584 weight gain Effects 0.000 description 10
210000004369 blood Anatomy 0.000 description 9
239000008280 blood Substances 0.000 description 9
230000003247 decreasing effect Effects 0.000 description 9
239000000243 solution Substances 0.000 description 9
239000004094 surface-active agent Substances 0.000 description 9
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical group OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 8
239000002202 Polyethylene glycol Substances 0.000 description 8
230000004071 biological effect Effects 0.000 description 8
208000035475 disorder Diseases 0.000 description 8
238000000338 in vitro Methods 0.000 description 8
235000018977 lysine Nutrition 0.000 description 8
239000000203 mixture Substances 0.000 description 8
201000010099 disease Diseases 0.000 description 7
238000010828 elution Methods 0.000 description 7
239000000463 material Substances 0.000 description 7
239000000047 product Substances 0.000 description 7
210000002966 serum Anatomy 0.000 description 7
229940124597 therapeutic agent Drugs 0.000 description 7
230000001225 therapeutic effect Effects 0.000 description 7
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 6
239000004472 Lysine Substances 0.000 description 6
102000004142 Trypsin Human genes 0.000 description 6
108090000631 Trypsin Proteins 0.000 description 6
125000003277 amino group Chemical group 0.000 description 6
239000003957 anion exchange resin Substances 0.000 description 6
239000003153 chemical reaction reagent Substances 0.000 description 6
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 6
230000000694 effects Effects 0.000 description 6
239000013628 high molecular weight specie Substances 0.000 description 6
238000004255 ion exchange chromatography Methods 0.000 description 6
229920001427 mPEG Polymers 0.000 description 6
230000004048 modification Effects 0.000 description 6
238000012986 modification Methods 0.000 description 6
230000002265 prevention Effects 0.000 description 6
238000000746 purification Methods 0.000 description 6
238000005932 reductive alkylation reaction Methods 0.000 description 6
230000004044 response Effects 0.000 description 6
239000012588 trypsin Substances 0.000 description 6
206010062767 Hypophysitis Diseases 0.000 description 5
102000048143 Insulin-Like Growth Factor II Human genes 0.000 description 5
108090001117 Insulin-Like Growth Factor II Proteins 0.000 description 5
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 5
201000010769 Prader-Willi syndrome Diseases 0.000 description 5
YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 5
NAVMQTYZDKMPEU-UHFFFAOYSA-N Targretin Chemical compound CC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(=C)C1=CC=C(C(O)=O)C=C1 NAVMQTYZDKMPEU-UHFFFAOYSA-N 0.000 description 5
230000032683 aging Effects 0.000 description 5
230000015572 biosynthetic process Effects 0.000 description 5
230000037396 body weight Effects 0.000 description 5
RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
229940088597 hormone Drugs 0.000 description 5
239000005556 hormone Substances 0.000 description 5
125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 5
210000003635 pituitary gland Anatomy 0.000 description 5
229920000233 poly(alkylene oxides) Polymers 0.000 description 5
230000002829 reductive effect Effects 0.000 description 5
150000003839 salts Chemical class 0.000 description 5
238000003998 size exclusion chromatography high performance liquid chromatography Methods 0.000 description 5
239000011780 sodium chloride Substances 0.000 description 5
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
102000004190 Enzymes Human genes 0.000 description 4
108090000790 Enzymes Proteins 0.000 description 4
239000012614 Q-Sepharose Substances 0.000 description 4
229920002684 Sepharose Polymers 0.000 description 4
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 4
238000004458 analytical method Methods 0.000 description 4
230000008901 benefit Effects 0.000 description 4
239000003729 cation exchange resin Substances 0.000 description 4
230000007423 decrease Effects 0.000 description 4
239000002552 dosage form Substances 0.000 description 4
229940079593 drug Drugs 0.000 description 4
238000003018 immunoassay Methods 0.000 description 4
230000001976 improved effect Effects 0.000 description 4
230000000670 limiting effect Effects 0.000 description 4
230000014759 maintenance of location Effects 0.000 description 4
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
PKWDZWYVIHVNKS-UHFFFAOYSA-N netoglitazone Chemical compound FC1=CC=CC=C1COC1=CC=C(C=C(CC2C(NC(=O)S2)=O)C=C2)C2=C1 PKWDZWYVIHVNKS-UHFFFAOYSA-N 0.000 description 4
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 4
230000001766 physiological effect Effects 0.000 description 4
HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 4
238000002360 preparation method Methods 0.000 description 4
108090000765 processed proteins & peptides Proteins 0.000 description 4
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
238000002965 ELISA Methods 0.000 description 3
239000007995 HEPES buffer Substances 0.000 description 3
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
102100022831 Somatoliberin Human genes 0.000 description 3
101710142969 Somatoliberin Proteins 0.000 description 3
230000004913 activation Effects 0.000 description 3
210000000577 adipose tissue Anatomy 0.000 description 3
125000002947 alkylene group Chemical group 0.000 description 3
238000005571 anion exchange chromatography Methods 0.000 description 3
230000000890 antigenic effect Effects 0.000 description 3
238000013459 approach Methods 0.000 description 3
238000003556 assay Methods 0.000 description 3
230000009286 beneficial effect Effects 0.000 description 3
210000000988 bone and bone Anatomy 0.000 description 3
230000015556 catabolic process Effects 0.000 description 3
229940023913 cation exchange resins Drugs 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
229920001577 copolymer Polymers 0.000 description 3
235000018417 cysteine Nutrition 0.000 description 3
230000002950 deficient Effects 0.000 description 3
238000006731 degradation reaction Methods 0.000 description 3
230000029087 digestion Effects 0.000 description 3
125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 3
239000012634 fragment Substances 0.000 description 3
239000004615 ingredient Substances 0.000 description 3
230000003993 interaction Effects 0.000 description 3
238000005259 measurement Methods 0.000 description 3
230000002503 metabolic effect Effects 0.000 description 3
230000001817 pituitary effect Effects 0.000 description 3
229920001515 polyalkylene glycol Chemical group 0.000 description 3
229920001184 polypeptide Polymers 0.000 description 3
150000003141 primary amines Chemical class 0.000 description 3
230000008569 process Effects 0.000 description 3
102000004196 processed proteins & peptides Human genes 0.000 description 3
230000009467 reduction Effects 0.000 description 3
238000006722 reduction reaction Methods 0.000 description 3
239000011347 resin Substances 0.000 description 3
229920005989 resin Polymers 0.000 description 3
238000000926 separation method Methods 0.000 description 3
238000001542 size-exclusion chromatography Methods 0.000 description 3
238000006467 substitution reaction Methods 0.000 description 3
210000002303 tibia Anatomy 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
230000001810 trypsinlike Effects 0.000 description 3
238000000108 ultra-filtration Methods 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
239000003643 water by type Substances 0.000 description 3
229920003169 water-soluble polymer Polymers 0.000 description 3
RVWNMGKSNGWLOL-GIIHNPQRSA-N (2s)-6-amino-2-[[(2r)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-amino-3-(1h-imidazol-5-yl)propanoyl]amino]-3-(2-methyl-1h-indol-3-yl)propanoyl]amino]propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]hexanamide Chemical compound C([C@H](N)C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CN=CN1 RVWNMGKSNGWLOL-GIIHNPQRSA-N 0.000 description 2
DEUOZXMBWOIDBW-UHFFFAOYSA-N 2-[2-[(5,6-dimethyl-1h-benzimidazol-2-yl)amino]-6-methyl-4-oxo-1h-pyrimidin-5-yl]acetic acid Chemical compound N1C=2C=C(C)C(C)=CC=2N=C1NC1=NC(=O)C(CC(O)=O)=C(C)N1 DEUOZXMBWOIDBW-UHFFFAOYSA-N 0.000 description 2
QBQLYIISSRXYKL-UHFFFAOYSA-N 4-[[4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl]methyl]-1,2-oxazolidine-3,5-dione Chemical compound CC=1OC(C=2C=CC=CC=2)=NC=1CCOC(C=C1)=CC=C1CC1C(=O)NOC1=O QBQLYIISSRXYKL-UHFFFAOYSA-N 0.000 description 2
208000030507 AIDS Diseases 0.000 description 2
ZTQSAGDEMFDKMZ-UHFFFAOYSA-N Butyraldehyde Chemical compound CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 description 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 2
229920002307 Dextran Polymers 0.000 description 2
206010021067 Hypopituitarism Diseases 0.000 description 2
108090000965 Insulin-like growth factor binding protein 3 Proteins 0.000 description 2
102100022708 Insulin-like growth factor-binding protein 3 Human genes 0.000 description 2
239000007987 MES buffer Substances 0.000 description 2
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
108010003044 Placental Lactogen Proteins 0.000 description 2
239000000381 Placental Lactogen Substances 0.000 description 2
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
150000001413 amino acids Chemical class 0.000 description 2
238000005349 anion exchange Methods 0.000 description 2
150000001450 anions Chemical class 0.000 description 2
239000005557 antagonist Substances 0.000 description 2
229960002938 bexarotene Drugs 0.000 description 2
229920001400 block copolymer Polymers 0.000 description 2
NNTOJPXOCKCMKR-UHFFFAOYSA-N boron;pyridine Chemical compound [B].C1=CC=NC=C1 NNTOJPXOCKCMKR-UHFFFAOYSA-N 0.000 description 2
108010006025 bovine growth hormone Proteins 0.000 description 2
229910052799 carbon Inorganic materials 0.000 description 2
210000004027 cell Anatomy 0.000 description 2
238000012512 characterization method Methods 0.000 description 2
238000007385 chemical modification Methods 0.000 description 2
239000003638 chemical reducing agent Substances 0.000 description 2
229960002896 clonidine Drugs 0.000 description 2
238000011260 co-administration Methods 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
230000021615 conjugation Effects 0.000 description 2
238000010168 coupling process Methods 0.000 description 2
238000005859 coupling reaction Methods 0.000 description 2
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
108010005905 delta-hGHR Proteins 0.000 description 2
JXMXDKHEZLKQPB-UHFFFAOYSA-N detomidine Chemical compound CC1=CC=CC(CC=2[N]C=NC=2)=C1C JXMXDKHEZLKQPB-UHFFFAOYSA-N 0.000 description 2
229960001894 detomidine Drugs 0.000 description 2
238000011161 development Methods 0.000 description 2
230000018109 developmental process Effects 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
239000012149 elution buffer Substances 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
238000009472 formulation Methods 0.000 description 2
150000002334 glycols Chemical class 0.000 description 2
239000003102 growth factor Substances 0.000 description 2
238000004128 high performance liquid chromatography Methods 0.000 description 2
229920001519 homopolymer Polymers 0.000 description 2
JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
238000004191 hydrophobic interaction chromatography Methods 0.000 description 2
230000005847 immunogenicity Effects 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
230000002608 insulinlike Effects 0.000 description 2
230000006651 lactation Effects 0.000 description 2
125000005647 linker group Chemical group 0.000 description 2
230000037356 lipid metabolism Effects 0.000 description 2
210000004185 liver Anatomy 0.000 description 2
208000018773 low birth weight Diseases 0.000 description 2
231100000533 low birth weight Toxicity 0.000 description 2
210000002540 macrophage Anatomy 0.000 description 2
HRLIOXLXPOHXTA-UHFFFAOYSA-N medetomidine Chemical compound C=1C=CC(C)=C(C)C=1C(C)C1=CN=C[N]1 HRLIOXLXPOHXTA-UHFFFAOYSA-N 0.000 description 2
229960002140 medetomidine Drugs 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
238000001543 one-way ANOVA Methods 0.000 description 2
238000012510 peptide mapping method Methods 0.000 description 2
229920002451 polyvinyl alcohol Polymers 0.000 description 2
230000001737 promoting effect Effects 0.000 description 2
125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 2
230000017854 proteolysis Effects 0.000 description 2
230000000717 retained effect Effects 0.000 description 2
238000012552 review Methods 0.000 description 2
229960004586 rosiglitazone Drugs 0.000 description 2
150000003335 secondary amines Chemical class 0.000 description 2
230000000580 secretagogue effect Effects 0.000 description 2
229940076279 serotonin Drugs 0.000 description 2
239000011734 sodium Substances 0.000 description 2
238000013223 sprague-dawley female rat Methods 0.000 description 2
230000004936 stimulating effect Effects 0.000 description 2
238000010254 subcutaneous injection Methods 0.000 description 2
239000007929 subcutaneous injection Substances 0.000 description 2
KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
229940099419 targretin Drugs 0.000 description 2
125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 2
GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 description 2
229960001641 troglitazone Drugs 0.000 description 2
GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 description 2
230000003442 weekly effect Effects 0.000 description 2
BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 2
229960001600 xylazine Drugs 0.000 description 2
XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
UTIMBUCRNZURQB-YFKPBYRVSA-N (2s)-2-(propylamino)propanoic acid Chemical compound CCCN[C@@H](C)C(O)=O UTIMBUCRNZURQB-YFKPBYRVSA-N 0.000 description 1
RDGUFKZGMLPVHL-QFIPXVFZSA-N (2s)-3-[4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl]-2-(propylamino)propanoic acid Chemical compound C1=CC(C[C@H](NCCC)C(O)=O)=CC=C1OCCC1=C(C)OC(C=2C=CC=CC=2)=N1 RDGUFKZGMLPVHL-QFIPXVFZSA-N 0.000 description 1
NWQWNCILOXTTHF-HLCSKTDOSA-N (2s)-6-amino-2-[[(2r)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-[[(2s)-2-aminopropanoyl]amino]-3-(1h-imidazol-5-yl)propanoyl]amino]-3-naphthalen-2-ylpropanoyl]amino]propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]hexanamide Chemical compound C([C@H](NC(=O)[C@@H](N)C)C(=O)N[C@H](CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CNC=N1 NWQWNCILOXTTHF-HLCSKTDOSA-N 0.000 description 1
WZHKXNSOCOQYQX-FUAFALNISA-N (2s)-6-amino-2-[[(2r)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-amino-3-(1h-imidazol-5-yl)propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]hexanamide Chemical compound C([C@H](N)C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CN=CN1 WZHKXNSOCOQYQX-FUAFALNISA-N 0.000 description 1
HRNLPPBUBKMZMT-SSSXJSFTSA-N (2s)-6-amino-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2r)-2-aminopropanoyl]amino]-3-naphthalen-2-ylpropanoyl]amino]propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]hexanamide Chemical compound C([C@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](C)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(=O)[C@H](N)C)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CC=CC=C1 HRNLPPBUBKMZMT-SSSXJSFTSA-N 0.000 description 1
WURGZWOTGMLDJP-ZCYANPAGSA-N (e)-5-amino-n,5-dimethyl-n-[(2r)-1-[methyl-[(2r)-1-(methylamino)-1-oxo-3-phenylpropan-2-yl]amino]-3-naphthalen-2-yl-1-oxopropan-2-yl]hex-2-enamide Chemical compound C([C@H](C(=O)NC)N(C)C(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)N(C)C(=O)\C=C\CC(C)(C)N)C1=CC=CC=C1 WURGZWOTGMLDJP-ZCYANPAGSA-N 0.000 description 1
NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 description 1
ASUGWWOMVNVWAW-UHFFFAOYSA-N 1-(2-methoxyethyl)pyrrole-2,5-dione Chemical compound COCCN1C(=O)C=CC1=O ASUGWWOMVNVWAW-UHFFFAOYSA-N 0.000 description 1
LEZWWPYKPKIXLL-UHFFFAOYSA-N 1-{2-(4-chlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound C1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 LEZWWPYKPKIXLL-UHFFFAOYSA-N 0.000 description 1
HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
XLKDJOPOOHHZAN-UHFFFAOYSA-N 1h-pyrrolo[2,3-c]pyridine Chemical class C1=NC=C2NC=CC2=C1 XLKDJOPOOHHZAN-UHFFFAOYSA-N 0.000 description 1
DCESWPKOLYIMNH-UHFFFAOYSA-N 2-(2,5-dioxopyrrolidin-1-yl)propanoic acid Chemical compound OC(=O)C(C)N1C(=O)CCC1=O DCESWPKOLYIMNH-UHFFFAOYSA-N 0.000 description 1
RHPNSIKQOSXFEA-UHFFFAOYSA-N 2-(2-aminopyrimidin-5-yl)acetic acid Chemical class NC1=NC=C(CC(O)=O)C=N1 RHPNSIKQOSXFEA-UHFFFAOYSA-N 0.000 description 1
KCEFVYIWOQSJCH-LMOVPXPDSA-N 2-[4-[2-[[(2r)-2-hydroxy-2-phenylethyl]amino]ethoxy]phenyl]acetic acid;hydrochloride Chemical compound Cl.C([C@H](O)C=1C=CC=CC=1)NCCOC1=CC=C(CC(O)=O)C=C1 KCEFVYIWOQSJCH-LMOVPXPDSA-N 0.000 description 1
BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
ILPUOPPYSQEBNJ-UHFFFAOYSA-N 2-methyl-2-phenoxypropanoic acid Chemical class OC(=O)C(C)(C)OC1=CC=CC=C1 ILPUOPPYSQEBNJ-UHFFFAOYSA-N 0.000 description 1
SXNMUZQWTWBSBL-UHFFFAOYSA-N 2h-cyclohepta[d][1,3]thiazole Chemical compound C1=CC=CC2=NCSC2=C1 SXNMUZQWTWBSBL-UHFFFAOYSA-N 0.000 description 1
CLPFFLWZZBQMAO-UHFFFAOYSA-N 4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl)benzonitrile Chemical compound C1=CC(C#N)=CC=C1C1N2C=NC=C2CCC1 CLPFFLWZZBQMAO-UHFFFAOYSA-N 0.000 description 1
PCAZCAZVHLGDBA-UHFFFAOYSA-N 5-[[4-(2-indol-1-ylethoxy)phenyl]methyl]-1,3-thiazolidine-2,4-dione Chemical compound S1C(=O)NC(=O)C1CC(C=C1)=CC=C1OCCN1C2=CC=CC=C2C=C1 PCAZCAZVHLGDBA-UHFFFAOYSA-N 0.000 description 1
IETKPTYAGKZLKY-UHFFFAOYSA-N 5-[[4-[(3-methyl-4-oxoquinazolin-2-yl)methoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione Chemical compound N=1C2=CC=CC=C2C(=O)N(C)C=1COC(C=C1)=CC=C1CC1SC(=O)NC1=O IETKPTYAGKZLKY-UHFFFAOYSA-N 0.000 description 1
ZLUWVRIZBDJIOF-UHFFFAOYSA-N 5-[[4-[[4-[(2,4-dioxo-1,3-thiazolidin-5-yl)methyl]phenyl]methyl]phenyl]methyl]-1,3-thiazolidine-2,4-dione Chemical compound S1C(=O)NC(=O)C1CC(C=C1)=CC=C1CC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 ZLUWVRIZBDJIOF-UHFFFAOYSA-N 0.000 description 1
DHSSDEDRBUKTQY-UHFFFAOYSA-N 6-prop-2-enyl-4,5,7,8-tetrahydrothiazolo[4,5-d]azepin-2-amine Chemical compound C1CN(CC=C)CCC2=C1N=C(N)S2 DHSSDEDRBUKTQY-UHFFFAOYSA-N 0.000 description 1
DJQOOSBJCLSSEY-UHFFFAOYSA-N Acipimox Chemical compound CC1=CN=C(C(O)=O)C=[N+]1[O-] DJQOOSBJCLSSEY-UHFFFAOYSA-N 0.000 description 1
102100033367 Appetite-regulating hormone Human genes 0.000 description 1
241000271566 Aves Species 0.000 description 1
239000007992 BES buffer Substances 0.000 description 1
229940123208 Biguanide Drugs 0.000 description 1
LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
102000014914 Carrier Proteins Human genes 0.000 description 1
102100021809 Chorionic somatomammotropin hormone 1 Human genes 0.000 description 1
KPSRODZRAIWAKH-JTQLQIEISA-N Ciprofibrate Natural products C1=CC(OC(C)(C)C(O)=O)=CC=C1[C@H]1C(Cl)(Cl)C1 KPSRODZRAIWAKH-JTQLQIEISA-N 0.000 description 1
229940126062 Compound A Drugs 0.000 description 1
201000003883 Cystic fibrosis Diseases 0.000 description 1
108020004414 DNA Proteins 0.000 description 1
108010016626 Dipeptides Proteins 0.000 description 1
102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 description 1
102000003779 Dipeptidyl-peptidases and tripeptidyl-peptidases Human genes 0.000 description 1
108090000194 Dipeptidyl-peptidases and tripeptidyl-peptidases Proteins 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 description 1
101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 description 1
101710115821 Flavin reductase (NADPH) Proteins 0.000 description 1
HEMJJKBWTPKOJG-UHFFFAOYSA-N Gemfibrozil Chemical compound CC1=CC=C(C)C(OCCCC(C)(C)C(O)=O)=C1 HEMJJKBWTPKOJG-UHFFFAOYSA-N 0.000 description 1
101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 description 1
102100033299 Glia-derived nexin Human genes 0.000 description 1
101710183811 Glia-derived nexin Proteins 0.000 description 1
102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
102100020948 Growth hormone receptor Human genes 0.000 description 1
101710119601 Growth hormone-releasing peptides Proteins 0.000 description 1
NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
241000282412 Homo Species 0.000 description 1
101001075374 Homo sapiens Gamma-glutamyl hydrolase Proteins 0.000 description 1
101001076292 Homo sapiens Insulin-like growth factor II Proteins 0.000 description 1
101001123448 Homo sapiens Prolactin receptor Proteins 0.000 description 1
101000664737 Homo sapiens Somatotropin Proteins 0.000 description 1
229940122355 Insulin sensitizer Drugs 0.000 description 1
108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
102100025947 Insulin-like growth factor II Human genes 0.000 description 1
VQTUBCCKSQIDNK-UHFFFAOYSA-N Isobutene Chemical group CC(C)=C VQTUBCCKSQIDNK-UHFFFAOYSA-N 0.000 description 1
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
208000017170 Lipid metabolism disease Diseases 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 1
102000004472 Myostatin Human genes 0.000 description 1
108010056852 Myostatin Proteins 0.000 description 1
PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical class OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
102000035195 Peptidases Human genes 0.000 description 1
102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 1
108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 1
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
102000004576 Placental Lactogen Human genes 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
102100024819 Prolactin Human genes 0.000 description 1
108010057464 Prolactin Proteins 0.000 description 1
108010002519 Prolactin Receptors Proteins 0.000 description 1
102100029000 Prolactin receptor Human genes 0.000 description 1
102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
101100288143 Rattus norvegicus Klkb1 gene Proteins 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
239000002262 Schiff base Substances 0.000 description 1
150000004753 Schiff bases Chemical class 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
102000013275 Somatomedins Human genes 0.000 description 1
102000005157 Somatostatin Human genes 0.000 description 1
108010056088 Somatostatin Proteins 0.000 description 1
239000012505 Superdex™ Substances 0.000 description 1
WBWWGRHZICKQGZ-UHFFFAOYSA-N Taurocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCCS(O)(=O)=O)C)C1(C)C(O)C2 WBWWGRHZICKQGZ-UHFFFAOYSA-N 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
230000001133 acceleration Effects 0.000 description 1
239000002253 acid Substances 0.000 description 1
229960003526 acipimox Drugs 0.000 description 1
229940062328 actos Drugs 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
108010083553 alanyl-histidyl-(2-naphthyl)alanyl-tryptophyl-phenylalanyl-lysinamide Proteins 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
230000001668 ameliorated effect Effects 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
235000001014 amino acid Nutrition 0.000 description 1
125000000539 amino acid group Chemical group 0.000 description 1
229940124325 anabolic agent Drugs 0.000 description 1
239000003263 anabolic agent Substances 0.000 description 1
229960002932 anastrozole Drugs 0.000 description 1
YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 1
150000008064 anhydrides Chemical class 0.000 description 1
238000010171 animal model Methods 0.000 description 1
239000003886 aromatase inhibitor Substances 0.000 description 1
229940046844 aromatase inhibitors Drugs 0.000 description 1
229940062310 avandia Drugs 0.000 description 1
235000021053 average weight gain Nutrition 0.000 description 1
ZSIQJIWKELUFRJ-UHFFFAOYSA-N azepane Chemical compound C1CCCNCC1 ZSIQJIWKELUFRJ-UHFFFAOYSA-N 0.000 description 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
229960000516 bezafibrate Drugs 0.000 description 1
IIBYAHWJQTYFKB-UHFFFAOYSA-N bezafibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1CCNC(=O)C1=CC=C(Cl)C=C1 IIBYAHWJQTYFKB-UHFFFAOYSA-N 0.000 description 1
150000004283 biguanides Chemical class 0.000 description 1
108091008324 binding proteins Proteins 0.000 description 1
239000000090 biomarker Substances 0.000 description 1
230000036765 blood level Effects 0.000 description 1
210000001124 body fluid Anatomy 0.000 description 1
230000008468 bone growth Effects 0.000 description 1
239000000337 buffer salt Substances 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000011575 calcium Substances 0.000 description 1
KVLLHLWBPNCVNR-SKCUWOTOSA-N capromorelin Chemical compound C([C@@]12CN(CCC1=NN(C2=O)C)C(=O)[C@@H](COCC=1C=CC=CC=1)NC(=O)C(C)(C)N)C1=CC=CC=C1 KVLLHLWBPNCVNR-SKCUWOTOSA-N 0.000 description 1
229950004826 capromorelin Drugs 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
230000004706 cardiovascular dysfunction Effects 0.000 description 1
238000005341 cation exchange Methods 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
238000000423 cell based assay Methods 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
238000001516 cell proliferation assay Methods 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
230000008859 change Effects 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
238000011210 chromatographic step Methods 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
239000012501 chromatography medium Substances 0.000 description 1
229960002174 ciprofibrate Drugs 0.000 description 1
KPSRODZRAIWAKH-UHFFFAOYSA-N ciprofibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1C1C(Cl)(Cl)C1 KPSRODZRAIWAKH-UHFFFAOYSA-N 0.000 description 1
229960001214 clofibrate Drugs 0.000 description 1
KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 1
239000002299 complementary DNA Substances 0.000 description 1
210000002808 connective tissue Anatomy 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
230000008878 coupling Effects 0.000 description 1
230000001186 cumulative effect Effects 0.000 description 1
230000001086 cytosolic effect Effects 0.000 description 1
238000004925 denaturation Methods 0.000 description 1
230000036425 denaturation Effects 0.000 description 1
239000003599 detergent Substances 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
230000001904 diabetogenic effect Effects 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
238000007865 diluting Methods 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
238000010494 dissociation reaction Methods 0.000 description 1
230000005593 dissociations Effects 0.000 description 1
229960003913 econazole Drugs 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
230000002124 endocrine Effects 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
HGVHMIAKUYLQLL-UHFFFAOYSA-N ethene;propane-1,2,3-triol Chemical compound C=C.OCC(O)CO HGVHMIAKUYLQLL-UHFFFAOYSA-N 0.000 description 1
125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
229950001583 examorelin Drugs 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
210000003722 extracellular fluid Anatomy 0.000 description 1
229950011548 fadrozole Drugs 0.000 description 1
235000013861 fat-free Nutrition 0.000 description 1
229960002297 fenofibrate Drugs 0.000 description 1
YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 1
238000000855 fermentation Methods 0.000 description 1
230000004151 fermentation Effects 0.000 description 1
229940125753 fibrate Drugs 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000012467 final product Substances 0.000 description 1
229960004421 formestane Drugs 0.000 description 1
OSVMTWJCGUFAOD-KZQROQTASA-N formestane Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1O OSVMTWJCGUFAOD-KZQROQTASA-N 0.000 description 1
238000005194 fractionation Methods 0.000 description 1
235000021588 free fatty acids Nutrition 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
108020001507 fusion proteins Proteins 0.000 description 1
102000037865 fusion proteins Human genes 0.000 description 1
238000005227 gel permeation chromatography Methods 0.000 description 1
229960003627 gemfibrozil Drugs 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
229940063135 genotropin Drugs 0.000 description 1
125000003827 glycol group Chemical group 0.000 description 1
XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical class C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 1
108010015153 growth hormone releasing hexapeptide Proteins 0.000 description 1
239000003324 growth hormone secretagogue Substances 0.000 description 1
108010085742 growth hormone-releasing peptide-2 Proteins 0.000 description 1
239000008241 heterogeneous mixture Substances 0.000 description 1
125000004836 hexamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
108010070965 hexarelin Proteins 0.000 description 1
229960000890 hydrocortisone Drugs 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
239000000960 hypophysis hormone Substances 0.000 description 1
230000002163 immunogen Effects 0.000 description 1
230000009851 immunogenic response Effects 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
CDAISMWEOUEBRE-UHFFFAOYSA-N inositol Chemical compound OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
229960000367 inositol Drugs 0.000 description 1
229940068935 insulin-like growth factor 2 Drugs 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
210000001596 intra-abdominal fat Anatomy 0.000 description 1
239000002563 ionic surfactant Substances 0.000 description 1
230000002427 irreversible effect Effects 0.000 description 1
238000002955 isolation Methods 0.000 description 1
239000000644 isotonic solution Substances 0.000 description 1
229960004125 ketoconazole Drugs 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
229960003881 letrozole Drugs 0.000 description 1
HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 1
230000004130 lipolysis Effects 0.000 description 1
YFVGRULMIQXYNE-UHFFFAOYSA-M lithium;dodecyl sulfate Chemical compound [Li+].CCCCCCCCCCCCOS([O-])(=O)=O YFVGRULMIQXYNE-UHFFFAOYSA-M 0.000 description 1
230000005923 long-lasting effect Effects 0.000 description 1
238000011866 long-term treatment Methods 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
108010000594 mecasermin Proteins 0.000 description 1
229960001311 mecasermin Drugs 0.000 description 1
239000012528 membrane Substances 0.000 description 1
206010027175 memory impairment Diseases 0.000 description 1
XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
229960003105 metformin Drugs 0.000 description 1
125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
229960002509 miconazole Drugs 0.000 description 1
239000011707 mineral Substances 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
230000035772 mutation Effects 0.000 description 1
229950001628 netoglitazone Drugs 0.000 description 1
239000002736 nonionic surfactant Substances 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
229960002446 octanoic acid Drugs 0.000 description 1
210000004789 organ system Anatomy 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
239000003002 pH adjusting agent Substances 0.000 description 1
238000012856 packing Methods 0.000 description 1
239000002245 particle Substances 0.000 description 1
125000004817 pentamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
230000003285 pharmacodynamic effect Effects 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
229910052698 phosphorus Inorganic materials 0.000 description 1
239000011574 phosphorus Substances 0.000 description 1
230000006461 physiological response Effects 0.000 description 1
229960005095 pioglitazone Drugs 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
229920003196 poly(1,3-dioxolane) Polymers 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
229920005862 polyol Polymers 0.000 description 1
150000003077 polyols Chemical class 0.000 description 1
229920001451 polypropylene glycol Polymers 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
230000004362 positive regulation of skeletal muscle tissue growth Effects 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
229960000208 pralmorelin Drugs 0.000 description 1
230000035935 pregnancy Effects 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
229940097325 prolactin Drugs 0.000 description 1
238000001742 protein purification Methods 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
239000012264 purified product Substances 0.000 description 1
150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
229920005604 random copolymer Polymers 0.000 description 1
108010077161 rat insulin-like growth factor-1 Proteins 0.000 description 1
239000011535 reaction buffer Substances 0.000 description 1
238000001525 receptor binding assay Methods 0.000 description 1
238000010188 recombinant method Methods 0.000 description 1
230000006798 recombination Effects 0.000 description 1
238000005215 recombination Methods 0.000 description 1
229950005713 reglitazar Drugs 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000013878 renal filtration Effects 0.000 description 1
238000004007 reversed phase HPLC Methods 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
SUFUKZSWUHZXAV-BTJKTKAUSA-N rosiglitazone maleate Chemical compound [H+].[H+].[O-]C(=O)\C=C/C([O-])=O.C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O SUFUKZSWUHZXAV-BTJKTKAUSA-N 0.000 description 1
238000005185 salting out Methods 0.000 description 1
238000005070 sampling Methods 0.000 description 1
125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 1
230000028327 secretion Effects 0.000 description 1
125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
238000004904 shortening Methods 0.000 description 1
238000002741 site-directed mutagenesis Methods 0.000 description 1
210000002356 skeleton Anatomy 0.000 description 1
230000000392 somatic effect Effects 0.000 description 1
NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
229960000553 somatostatin Drugs 0.000 description 1
108700031632 somatrem Proteins 0.000 description 1
229960003259 somatrem Drugs 0.000 description 1
229960004532 somatropin Drugs 0.000 description 1
238000013222 sprague-dawley male rat Methods 0.000 description 1
238000010186 staining Methods 0.000 description 1
239000000758 substrate Substances 0.000 description 1
239000001384 succinic acid Substances 0.000 description 1
KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
108010064878 tabimorelin Proteins 0.000 description 1
229950008131 tabimorelin Drugs 0.000 description 1
WBWWGRHZICKQGZ-GIHLXUJPSA-N taurocholic acid Chemical compound C([C@@H]1C[C@H]2O)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@H](O)C1 WBWWGRHZICKQGZ-GIHLXUJPSA-N 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
125000004149 thio group Chemical group *S* 0.000 description 1
230000030968 tissue homeostasis Effects 0.000 description 1
238000013519 translation Methods 0.000 description 1
UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
125000003258 trimethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])[*:1] 0.000 description 1
GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
HGBOYTHUEUWSSQ-UHFFFAOYSA-N valeric aldehyde Natural products CCCCC=O HGBOYTHUEUWSSQ-UHFFFAOYSA-N 0.000 description 1
210000001835 viscera Anatomy 0.000 description 1
238000005303 weighing Methods 0.000 description 1
230000004580 weight loss Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Chemistry (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Endocrinology (AREA)
Physical Education & Sports Medicine (AREA)
Neurology (AREA)
Orthopedic Medicine & Surgery (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Reproductive Health (AREA)
Epidemiology (AREA)
Rheumatology (AREA)
Diabetes (AREA)
Psychiatry (AREA)
Urology & Nephrology (AREA)
Gynecology & Obstetrics (AREA)
Hospice & Palliative Care (AREA)
Cardiology (AREA)
Vascular Medicine (AREA)
Pain & Pain Management (AREA)
Pregnancy & Childbirth (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Heart & Thoracic Surgery (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

JP2007529040A 2004-08-31 2005-08-25 グリセロール分岐のポリエチレングリコール−ヒト成長ホルモン結合体、それらの製造方法及び使用方法 Pending JP2008511610A (ja)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US60594504P	2004-08-31	2004-08-31
PCT/IB2005/002939 WO2006024953A2 (en)	2004-08-31	2005-08-25	Glycerol branched polyethylene glycol human growth hormone conjugates, process for their preparation, and methods of use thereof

Publications (1)

Publication Number	Publication Date
JP2008511610A true JP2008511610A (ja)	2008-04-17

Family

ID=35708806

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2007529040A Pending JP2008511610A (ja)	2004-08-31	2005-08-25	グリセロール分岐のポリエチレングリコール−ヒト成長ホルモン結合体、それらの製造方法及び使用方法

Country Status (24)

Country	Link
EP (1)	EP1789092A2 (es)
JP (1)	JP2008511610A (es)
KR (1)	KR20070042567A (es)
CN (1)	CN101010105A (es)
AP (1)	AP2007003919A0 (es)
AR (1)	AR050851A1 (es)
AU (1)	AU2005278903A1 (es)
BR (1)	BRPI0515118A (es)
CA (1)	CA2577999A1 (es)
CR (1)	CR8942A (es)
EA (1)	EA200700380A1 (es)
EC (1)	ECSP077281A (es)
GT (1)	GT200500235A (es)
IL (1)	IL181085A0 (es)
MA (1)	MA28908B1 (es)
MX (1)	MX2007002441A (es)
NL (1)	NL1029828C2 (es)
NO (1)	NO20071322L (es)
PE (1)	PE20060654A1 (es)
TN (1)	TNSN07078A1 (es)
TW (1)	TW200621291A (es)
UY (1)	UY29088A1 (es)
WO (1)	WO2006024953A2 (es)
ZA (1)	ZA200701802B (es)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2021508715A (ja) *	2017-12-29	2021-03-11	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	Ｐｅｇ化タンパク質組成物を提供するための方法
JP2021508706A (ja) *	2017-12-29	2021-03-11	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	Ｐｅｇ化タンパク質組成物を提供するための方法

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU751898B2 (en)	1997-07-14	2002-08-29	Bolder Biotechnology, Inc.	Derivatives of growth hormone and related proteins
US7495087B2 (en)	1997-07-14	2009-02-24	Bolder Biotechnology, Inc.	Cysteine muteins in the C-D loop of human interleukin-11
KR100731826B1 (ko)	1999-01-14	2007-06-22	볼더 바이오테크놀로지 인코퍼레이티드	유리 시스테인 잔기를 함유하는 단백질의 제조 방법
US7855279B2 (en)	2005-09-27	2010-12-21	Amunix Operating, Inc.	Unstructured recombinant polymers and uses thereof
EP1834963A1 (en) *	2006-03-13	2007-09-19	Siegfried Ltd.	Di-polymer protein conjugates and processes for their preparation
JP2009536963A (ja) *	2006-05-12	2009-10-22	ドン・ア・ファーム・カンパニー・リミテッド	ポリエチレングリコール−インターフェロンα結合体
JP2008069073A (ja) *	2006-09-12	2008-03-27	Yokohama Tlo Co Ltd	ラクトフェリン複合体及びその製造方法
KR101079993B1 (ko)	2006-11-17	2011-11-04	동아제약주식회사	폴리에틸렌글리콜 과립구 콜로니 자극인자 접합체
CL2008002399A1 (es)	2007-08-16	2009-01-02	Pharmaessentia Corp	Conjugado sustancialmente puro que posee una porcion polimerica, una porcion proteica (interferon alfa 2b) y un ligante alifatico de 1 a 10 atomos de carbono, util en el tratamiento de las hepatitis b o c.
CN102112493B (zh) *	2008-07-23	2015-04-01	韩美科学株式会社	包含具有三个官能性末端的非肽基聚合物的多肽复合物
CN102131844B (zh)	2008-07-31	2016-03-02	药华医药股份有限公司	肽-聚合物缀合物
US8535655B2 (en)	2008-10-10	2013-09-17	Polyactiva Pty Ltd.	Biodegradable polymer—bioactive moiety conjugates
EP2340271B1 (en) *	2008-10-10	2018-12-05	PolyActiva Pty Ltd.	Polymer-bioactive agent conjugates
KR101726715B1 (ko) *	2008-10-10	2017-04-13	폴리액티바 피티와이 리미티드	생분해성 폴리머-생물활성 모이어티 공액체
CN108530543B (zh)	2009-02-03	2023-06-23	阿穆尼克斯制药公司	延伸重组多肽和包含该延伸重组多肽的组合物
US8703717B2 (en)	2009-02-03	2014-04-22	Amunix Operating Inc.	Growth hormone polypeptides and methods of making and using same
US8680050B2 (en)	2009-02-03	2014-03-25	Amunix Operating Inc.	Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
US9849188B2 (en)	2009-06-08	2017-12-26	Amunix Operating Inc.	Growth hormone polypeptides and methods of making and using same
US8841249B2 (en)	2009-08-06	2014-09-23	Novo Nordisk A/S	Growth hormones with prolonged in-vivo efficacy
CN101831067A (zh) *	2010-05-31	2010-09-15	王二新	聚乙二醇脂类缀合物及其在制备药物中的应用
EP2446898A1 (en)	2010-09-30	2012-05-02	Laboratorios Del. Dr. Esteve, S.A.	Use of growth hormone to enhance the immune response in immunosuppressed patients
CN102367290B (zh) *	2011-04-26	2013-05-08	厦门赛诺邦格生物科技有限公司	链官能化的多级支化聚乙二醇及其合成方法
PE20142451A1 (es) *	2012-02-27	2015-02-04	Amunix Operating Inc	Composiciones de conjugados de xten y metodos para realizar las mismas
DK2947111T3 (en) *	2013-01-17	2018-05-07	Xiamen Sinopeg Biotech Co Ltd	MONOFUNCTIONAL BRANCHED POLYETHYLENE LYCOL AND BIORELATED SUBSTANCE MODIFIED BY SAME
CN104877127B (zh)	2015-06-23	2017-11-10	厦门赛诺邦格生物科技股份有限公司	一种八臂聚乙二醇衍生物、制备方法及其修饰的生物相关物质
SI3215193T1 (sl)	2014-11-06	2024-02-29	Pharmaessentia Corporation	Dozirna shema za pegiliran interferon
ES2905105T3 (es)	2017-12-29	2022-04-07	Hoffmann La Roche	Procedimiento para proporcionar una composición de proteína PEGilada

Citations (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1993000109A1 (en) *	1991-06-28	1993-01-07	Genentech, Inc.	Method of stimulating immune response using growth hormone
JPH10139877A (ja) *	1996-11-05	1998-05-26	Nof Corp	コハク酸イミジル基置換ポリオキシアルキレン誘導体の製造方法
JPH11228685A (ja) *	1998-02-12	1999-08-24	Nof Corp	カルボキシル基含有ポリオキシアルキレン化合物
JP2001510033A (ja) *	1997-07-14	2001-07-31	ボルダーバイオテクノロジー，インコーポレイテッド	成長ホルモンおよび関連タンパク質の誘導体
JP2002534119A (ja) *	1999-01-14	2002-10-15	ボルダーバイオテクノロジー，インコーポレイテッド	自由システイン残基を有するタンパク質の生産方法
WO2003044056A2 (en) *	2001-11-20	2003-05-30	Pharmacia Corporation	Chemically-modified human growth hormone conjugates
WO2004022630A2 (en) *	2002-09-09	2004-03-18	Nektar Therapeutics Al, Corporation	Water-soluble polymer alkanals
WO2004046222A1 (ja) *	2002-11-20	2004-06-03	Nof Corporation	修飾された生体関連物質、その製造方法および中間体
WO2004060406A2 (en) *	2002-12-31	2004-07-22	Nektar Therapeutics Al, Corporation	Polymeric reagents comprising a ketone or a related functional group

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN1747748B (zh) *	2003-05-23	2011-01-19	尼克塔治疗公司	具有特定原子排列的聚合物衍生物

2005
- 2005-08-25 EP EP05784225A patent/EP1789092A2/en not_active Withdrawn
- 2005-08-25 CN CNA2005800291171A patent/CN101010105A/zh active Pending
- 2005-08-25 AP AP2007003919A patent/AP2007003919A0/xx unknown
- 2005-08-25 EA EA200700380A patent/EA200700380A1/ru unknown
- 2005-08-25 WO PCT/IB2005/002939 patent/WO2006024953A2/en not_active Ceased
- 2005-08-25 CA CA002577999A patent/CA2577999A1/en not_active Abandoned
- 2005-08-25 BR BRPI0515118-0A patent/BRPI0515118A/pt not_active IP Right Cessation
- 2005-08-25 AU AU2005278903A patent/AU2005278903A1/en not_active Abandoned
- 2005-08-25 KR KR1020077004912A patent/KR20070042567A/ko not_active Ceased
- 2005-08-25 MX MX2007002441A patent/MX2007002441A/es unknown
- 2005-08-25 JP JP2007529040A patent/JP2008511610A/ja active Pending
- 2005-08-26 PE PE2005000991A patent/PE20060654A1/es not_active Application Discontinuation
- 2005-08-29 AR ARP050103612A patent/AR050851A1/es unknown
- 2005-08-29 UY UY29088A patent/UY29088A1/es not_active Application Discontinuation
- 2005-08-30 TW TW094129583A patent/TW200621291A/zh unknown
- 2005-08-30 GT GT200500235A patent/GT200500235A/es unknown
- 2005-08-30 NL NL1029828A patent/NL1029828C2/nl not_active IP Right Cessation
2007
- 2007-01-31 IL IL181085A patent/IL181085A0/en unknown
- 2007-02-26 CR CR8942A patent/CR8942A/es not_active Application Discontinuation
- 2007-02-27 EC EC2007007281A patent/ECSP077281A/es unknown
- 2007-02-27 TN TNP2007000078A patent/TNSN07078A1/fr unknown
- 2007-02-28 MA MA29724A patent/MA28908B1/fr unknown
- 2007-02-28 ZA ZA200701802A patent/ZA200701802B/xx unknown
- 2007-03-09 NO NO20071322A patent/NO20071322L/no not_active Application Discontinuation

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1993000109A1 (en) *	1991-06-28	1993-01-07	Genentech, Inc.	Method of stimulating immune response using growth hormone
JPH10139877A (ja) *	1996-11-05	1998-05-26	Nof Corp	コハク酸イミジル基置換ポリオキシアルキレン誘導体の製造方法
JP2001510033A (ja) *	1997-07-14	2001-07-31	ボルダーバイオテクノロジー，インコーポレイテッド	成長ホルモンおよび関連タンパク質の誘導体
JPH11228685A (ja) *	1998-02-12	1999-08-24	Nof Corp	カルボキシル基含有ポリオキシアルキレン化合物
JP2002534119A (ja) *	1999-01-14	2002-10-15	ボルダーバイオテクノロジー，インコーポレイテッド	自由システイン残基を有するタンパク質の生産方法
WO2003044056A2 (en) *	2001-11-20	2003-05-30	Pharmacia Corporation	Chemically-modified human growth hormone conjugates
WO2004022630A2 (en) *	2002-09-09	2004-03-18	Nektar Therapeutics Al, Corporation	Water-soluble polymer alkanals
WO2004046222A1 (ja) *	2002-11-20	2004-06-03	Nof Corporation	修飾された生体関連物質、その製造方法および中間体
WO2004060406A2 (en) *	2002-12-31	2004-07-22	Nektar Therapeutics Al, Corporation	Polymeric reagents comprising a ketone or a related functional group

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ＪＯＵＲＮＡＬＯＦＢＩＯＬＯＧＩＣＡＬＣＨＥＭＩＳＴＲＹ, vol. 271, no. 36, JPN4007021764, 1996, pages 21969 - 21977, ISSN: 0000890251 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2021508715A (ja) *	2017-12-29	2021-03-11	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	Ｐｅｇ化タンパク質組成物を提供するための方法
JP2021508706A (ja) *	2017-12-29	2021-03-11	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	Ｐｅｇ化タンパク質組成物を提供するための方法
JP7137625B2 (ja)	2017-12-29	2022-09-14	エフ．ホフマン－ラロシュアーゲー	Ｐｅｇ化タンパク質組成物を提供するための方法
JP2022169794A (ja) *	2017-12-29	2022-11-09	エフ．ホフマン－ラロシュアーゲー	Ｐｅｇ化タンパク質組成物を提供するための方法
JP7227633B2 (ja)	2017-12-29	2023-02-22	エフ．ホフマン－ラロシュエージー．	Ｐｅｇ化タンパク質組成物を提供するための方法
JP2023055876A (ja) *	2017-12-29	2023-04-18	エフ．ホフマン－ラロシュアーゲー	Ｐｅｇ化タンパク質組成物を提供するための方法
JP7541555B2 (ja)	2017-12-29	2024-08-28	エフ．ホフマン－ラロシュアーゲー	Ｐｅｇ化タンパク質組成物を提供するための方法

Also Published As

Publication number	Publication date
CA2577999A1 (en)	2006-03-09
NO20071322L (no)	2007-05-29
TW200621291A (en)	2006-07-01
MX2007002441A (es)	2007-05-04
ECSP077281A (es)	2007-03-29
MA28908B1 (fr)	2007-10-01
GT200500235A (es)	2006-03-21
WO2006024953A3 (en)	2007-01-18
CN101010105A (zh)	2007-08-01
EP1789092A2 (en)	2007-05-30
AP2007003919A0 (en)	2007-02-28
PE20060654A1 (es)	2006-08-12
IL181085A0 (en)	2007-07-04
UY29088A1 (es)	2006-03-31
AU2005278903A1 (en)	2006-03-09
ZA200701802B (en)	2008-08-27
CR8942A (es)	2007-08-16
NL1029828A1 (nl)	2006-03-01
EA200700380A1 (ru)	2007-10-26
WO2006024953A2 (en)	2006-03-09
TNSN07078A1 (fr)	2008-06-02
BRPI0515118A (pt)	2008-07-01
KR20070042567A (ko)	2007-04-23
AR050851A1 (es)	2006-11-29
NL1029828C2 (nl)	2006-10-20

Publication	Publication Date	Title
EP1715887B1 (en)	2007-06-20	N-terminally monopegylated human growth hormone conjugates, process for their preparation, and use thereof
JP2008511610A (ja)	2008-04-17	グリセロール分岐のポリエチレングリコール−ヒト成長ホルモン結合体、それらの製造方法及び使用方法
KR20050044858A (ko)	2005-05-13	화학적으로 개질된 인간 성장 호르몬 콘쥬게이트
US20030171285A1 (en)	2003-09-11	Chemically-modified human growth hormone conjugates
US20040127417A1 (en)	2004-07-01	N-terminally monopegylated human growth hormone conjugates and process for their preparation
US20040038892A1 (en)	2004-02-26	Chemically-modified human growth hormone conjugates
HK1104913A (en)	2008-01-25	Glycerol branched polyethylene glycol human growth hormone conjugates, process for their preparation, and methods of use thereof
MXPA06008888A (es)	2007-04-10	Conjugados de la hormona del crecimiento humana monopegilados en el extremo n, procedimiento para su preparacion y metodos para usarlos
HK1098360A (en)	2007-07-20	N-terminally monopegylated human growth hormone conjugates, process for their preparation, and methods of use thereof

Legal Events

Date	Code	Title	Description
2008-03-04	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080303
2008-04-02	A02	Decision of refusal	Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20080401

Date

Code

Title

Description

2008-03-04

A521

Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080303

2008-04-02

A02

Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20080401